Ciruelos, E., Apellániz‐Ruiz, M., Cantos, B., Martinez‐Jáñez, N., Bueno‐Muiño, C., Echarri, M., . . . Sepúlveda, J. (2019). A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel as the First‐Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2‐Negative Metastatic Breast Cancer. Oncologist.
Chicago Style CitationCiruelos, Eva, et al. "A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel As the First‐Line Treatment for Patients With Human Epidermal Growth Factor Receptor Type 2‐Negative Metastatic Breast Cancer." Oncologist 2019.
Cita MLACiruelos, Eva, et al. "A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel As the First‐Line Treatment for Patients With Human Epidermal Growth Factor Receptor Type 2‐Negative Metastatic Breast Cancer." Oncologist 2019.